TGFβ signaling in the tumor microenvironment inhibits the anti-tumor function of a variety of immune cell populations, including T cells and natural killer cells, and the resulting immunosuppression severely limits the efficacy of immune checkpoint inhibitors and other immunotherapy approaches. The gene discussed is TGFB1; the disease is neoplasm.